MPS Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsInvestor Communications View source PDF

MPSLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.7%1-day move

₹1810.00

prior close

₹1834.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-3.3-1.1-1.6-0.3+0.7+0.7-1.8-1.4-1.2+1.3+2.0+0.6+14.5—

Up moveDown movePending

AI summary

MPS Limited delivered record FY26 performance with EPS of ₹102.11, up 16.3% YoY, and EBITDA of ₹236 Cr (30.7% margin). Q4 FY26 revenue grew 12.66% YoY to ₹205.16 Cr with EBITDA up 20.53%. The company guides for FY27 EBITDA of ₹300+ Cr, implying ~21% 3-year CAGR from FY24 (₹169 Cr) to FY27. Research segment anchors at 58.3% revenue with 39.9% FY26 EBITDA margin. Unbound Medicine acquisition (Feb 2026) added healthcare knowledge capabilities with 97% gross retention. Corporate Learning EBITDA rebounded 55% QoQ after restructuring. North America accounts for 50% of FY26 revenue. Cash position strong at ₹113.75 Cr with borrowings of ₹40.25 Cr.

Likely market impact

MPS delivered strong margin expansion with 30.7% EBITDA margin, and the FY27 guidance of ₹300+ Cr signals continued earnings compounding. The stock benefits from diversified revenue mix (Research 60%, Education 21%, Corporate Learning 13%) and AI-first product deployment across all segments.